What We Offer
MassMatrix is poised to revolutionize the discovery, quality assurance, and quality control of synthetic RNA-based drugs and therapies.
The gene editing and therapy market is projected to reach $36 billion in five years, MassMatrix's innovative solution to RNA sequencing is poised to capture a significant share of this rapidly expanding market.